Association of androgen receptor signal, radiosensitivity and DNA repair pathway in urothelial carcinoma

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K18621
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56030:Urology-related
• Research Institution: Keio University
• Principal Investigator: Murakami Tetsushi 慶應義塾大学, 医学部(信濃町), 助教 (40813655)
• Project Period (FY): 2019-04-01 – 2021-03-31
• Keywords: 尿路上皮癌 / PARP阻害剤 / DNA修復機構 / アンドロゲン受容体

Outline of Final Research Achievements

We examined the efficacy of combination therapy with anti-androgenic agent, radiotherapy and PARP inhibitor for bladder cancer cell line: 5637 with androgen receptor expression. 5637-AR cells revealed anti-androgenic agent and PARP inhibitor enhanced radiosensitivity. Combined administration of PARP inhibitor and anti-androgenic agent didn’t showed higher anti-tumor effect than single agent.

Free Research Field

尿路上皮癌

Academic Significance and Societal Importance of the Research Achievements

PARP阻害剤は実臨床において卵巣癌、乳癌、前立腺癌、膵癌に適応があり、本研究ではPARP阻害剤の膀胱癌における有効性について検証した。